Back to Search
Start Over
[Incidence and mortality of central nervous system tumors in France: trends over the period 1978-2000 and influence of registration practices on results]
- Source :
- Epidemiology and Public Health / Revue d'Epidémiologie et de Santé Publique, Epidemiology and Public Health / Revue d'Epidémiologie et de Santé Publique, Elsevier Masson, 2006, 54 (5), pp.399-406
- Publication Year :
- 2006
-
Abstract
- International audience; BACKGROUND: In France, cancer incidence figures are produced by cancer registries covering only 13.5% to 16% of the whole population of the country. Thus, to produce national figures, estimates have to be computed. Registration disparities between registries concerning tumors of the Central Nervous System (CNS) could have biased these estimates. METHODS: National estimates are based on modelling of the incidence/mortality ratio. The most recent estimations for year 2000 were calculated by the French Cancer Registry Network (FRANCIM) and the department of biostatistics of Lyon University Hospital. Since benign tumors are not recorded in some cancer registries, a new estimate of the incidence of CNS tumors was produced by estimating the number of benign tumors in these registries. RESULTS: In 2000 in France, the number of estimated cases of CNS tumors was 2697 in men and 2602 in women, with incidence rates (World standard) of 7.4 and 6.4 per 100,000 respectively. The incidence increased between 1978 and 2000, on an average by 2.25% per year in men and 3.01% per year in women. However, these estimates do not provide a correct picture of CNS incidence. First of all, pathological diagnoses are not performed in 3.5%-27.5% of the patients with CNS tumors registered in French registries. Second, figures for benign tumors (mainly meningiomas) were provided by only two of nine cancer registries. If benign tumors had been registered by all cancer registries, computed incidence would have increased by 12% for men and 26% for women. CONCLUSION: Incidence of CNS tumors is increasing in France, as in many other countries. To improve comparability with other countries, French cancer registries should also collect data on benign tumors. The discrepancies observed between registries in the proportion of patients without information on histology show differences in diagnostic practices and should be the starting point for a survey on this topic.
- Subjects :
- Male
MESH: Survival Rate
MESH: Registries
MESH : Retrospective Studies
MESH : Sex Factors
MESH : Male
MESH : Aged
[SDV.CAN]Life Sciences [q-bio]/Cancer
MESH : Central Nervous System Neoplasms
MESH: Central Nervous System Neoplasms
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
Central Nervous System Neoplasms
Sex Factors
MESH: Sex Factors
[SDV.CAN] Life Sciences [q-bio]/Cancer
MESH: Risk Factors
Risk Factors
Humans
MESH : Female
MESH : Middle Aged
MESH: Incidence
Registries
MESH : France
Aged
Retrospective Studies
MESH: Aged
MESH: Humans
MESH: Middle Aged
Incidence
MESH : Humans
MESH: Retrospective Studies
Middle Aged
MESH : Survival Rate
MESH : Risk Factors
MESH: Male
MESH : Incidence
MESH: France
Survival Rate
Female
France
MESH: Female
MESH : Registries
Subjects
Details
- Language :
- French
- ISSN :
- 03987620
- Volume :
- 54
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Revue d'epidemiologie et de sante publique
- Accession number :
- edsair.pmid.dedup....dc3d262f1b04580f12857a7874990d3f